157 related articles for article (PubMed ID: 34416629)
1. Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression.
Saber S; Nasr M; Saad AS; Mourad AAE; Gobba NA; Shata A; Hafez AM; Elsergany RN; Elagamy HI; El-Ahwany E; Amin NA; Girgis S; Elewa YHA; Mahmoud MH; Batiha GE; El-Rous MA; Kamal I; Kaddah MMY; Khodir AE
Biomed Pharmacother; 2021 Oct; 142():112029. PubMed ID: 34416629
[TBL] [Abstract][Full Text] [Related]
2. Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells.
Zhou F; Du J; Wang J
Mol Cell Biochem; 2017 Apr; 428(1-2):171-178. PubMed ID: 28063005
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
Pourgholami MH; Cai ZY; Badar S; Wangoo K; Poruchynsky MS; Morris DL
BMC Cancer; 2010 Apr; 10():143. PubMed ID: 20398289
[TBL] [Abstract][Full Text] [Related]
4. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
5. Roles of p300 and cyclic adenosine monophosphate response element binding protein in high glucose-induced hypoxia-inducible factor 1α inactivation under hypoxic conditions.
Ding L; Yang M; Zhao T; Lv G
J Diabetes Investig; 2017 May; 8(3):277-285. PubMed ID: 27808477
[TBL] [Abstract][Full Text] [Related]
6. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
7. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
[TBL] [Abstract][Full Text] [Related]
8. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
Noorani L; Stenzel M; Liang R; Pourgholami MH; Morris DL
J Nanobiotechnology; 2015 Mar; 13():25. PubMed ID: 25890381
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
Saber S; Khodir AE; Soliman WE; Salama MM; Abdo WS; Elsaeed B; Nader K; Abdelnasser A; Megahed N; Basuony M; Shawky A; Mahmoud M; Medhat R; Eldin AS
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1591-1604. PubMed ID: 31367864
[TBL] [Abstract][Full Text] [Related]
12. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats.
Liu Y; Wang XQ; Ren WX; Chen YL; Yu Y; Zhang JK; Bawudong D; Gu JP; Xu XD; Zhang XN
J Biomed Mater Res B Appl Biomater; 2013 Aug; 101(6):998-1005. PubMed ID: 23529958
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Kandil EA; Sayed RH; Ahmed LA; Abd El Fattah MA; El-Sayeh BM
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1141-1150. PubMed ID: 31408200
[TBL] [Abstract][Full Text] [Related]
14. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Nasr M; Selima E; Hamed O; Kazem A
Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1
Li X; Tsauo J; Geng C; Zhao H; Lei X; Li X
Am J Chin Med; 2018; 46(8):1915-1931. PubMed ID: 30525897
[TBL] [Abstract][Full Text] [Related]
17. AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma.
Abd El-Fattah EE; Saber S; Youssef ME; Eissa H; El-Ahwany E; Amin NA; Alqarni M; Batiha GE; Obaidullah AJ; Kaddah MMY; Ahmed Gaafar AG; Mourad AAE; Mostafa-Hedeab G; Abdelhamid AM
Front Pharmacol; 2021; 12():720173. PubMed ID: 35095479
[TBL] [Abstract][Full Text] [Related]
18. Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling.
Saber S; El-Fattah EEA; Abdelhamid AM; Mourad AAE; Hamouda MAM; Elrabat A; Zakaria S; Haleem AA; Mohamed SZ; Elgharabawy RM; Morsy NE; El Adle Khalaf N; Mohammed OA; El-Bahouty WB; Mostafa SA; Abdelhady R; Galal O; ElSaid ZH; Yahya G; Shata A; Youssef ME
Biomed Pharmacother; 2023 Feb; 158():114196. PubMed ID: 36916405
[TBL] [Abstract][Full Text] [Related]
19. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
20. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
